Cagrilintide vs Orforglipron

Cagrilintide and Orforglipron represent divergent approaches to modulating appetite and metabolism. Cagrilintide, a synthetic amylin analog developed by Novo Nordisk, acts on hindbrain satiety centers and is often studied in combination with semaglutide (CagriSema). Orforglipron, from Eli Lilly, is a non-peptide oral GLP-1 receptor agonist in Phase III trials, offering once-daily dosing without food restrictions. Their mechanisms, evidence maturity, and safety profiles differ substantially, making direct comparison valuable for researchers selecting investigational tools.

Cagrilintide is a long-acting synthetic analog of human amylin, co-secreted with insulin by pancreatic beta cells. It activates amylin receptors in the area postrema, promoting satiety via hindbrain pathways. In the REDEFINE Phase III program, the CagriSema combination (Cagrilintide plus semaglutide) achieved 20.4% weight loss at 68 weeks, surpassing semaglutide alone. Novo Nordisk filed for FDA approval in 2026. Research suggests synergy between amylin and GLP-1 agonism, potentially reducing required doses of each. Key claims include ~20% weight loss with CagriSema, superiority over semaglutide monotherapy, and standalone efficacy for weight management.

Orforglipron (LY3502970) is a small-molecule, non-peptide oral GLP-1 receptor agonist developed by Eli Lilly. Unlike peptide-based GLP-1 agonists, it is a synthetic small molecule included here for comparative analysis. It is in Phase III development (ATTAIN program) for type 2 diabetes and obesity. Phase II results show weight loss approaching that of injectable GLP-1 agonists, with once-daily oral dosing unrestricted by food intake—potentially more convenient than oral semaglutide. Key claims include significant weight loss, effective glycemic control in T2D, and a convenient oral regimen without meal timing constraints.

Both Cagrilintide and Orforglipron are primarily studied for weight management and metabolic health, including obesity and type 2 diabetes. Cagrilintide is also investigated in combination with semaglutide for enhanced weight loss, while Orforglipron is explored as an oral alternative to injectable GLP-1 agonists. No additional unique applications are reported for either agent beyond these metabolic endpoints. Researchers may select based on mechanism preference—amylin vs. GLP-1—or dosing route.

Cagrilintide: In CagriSema trials, gastrointestinal adverse events occurred in 79.6% of participants (vs. 39.9% placebo), including nausea, vomiting, diarrhea, and constipation. These were mainly transient and mild-to-moderate. Class-level risks include pancreatitis, gallbladder events, and thyroid C-cell tumors in rodents. Orforglipron: Common GI events include nausea (30–40%), vomiting (14–22%), and diarrhea (16–22%), consistent with GLP-1 class but lower than danuglipron BID. Events are dose-dependent and transient, most frequent during titration. Discontinuation due to GI effects is approximately 10–17%, lower than danuglipron BID. Both require monitoring for GI tolerability.